glp-1 receptor agonists benefits and cardiovascular outcome trials: An update GLP-1 receptor agonists for cardiovascular

Zambonino MC, Quizhpe EM, Jaramillo FE, Rahman A, Santiago Vispo N, Jeffryes C, et al

Therefore, it is tempting to speculate that the high-fat milk contains molecules that orchestrate cardiomyocyte maturation, and that manipulating the nutrition supply or inhibiting fatty acid oxidation could potentially revert cardiomyocytes to a more immature, regenerative state

Dramsdahl M, Ersland L, Plessen KJ, Haavik J, Hugdahl K, Specht K

Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein

The comparison between GLP-1RA and SGLT-2 inhibitors also show no difference in their risk for MACE (RR = 0.98, 95% CI 0.911.07)

Do not combine with Lexapro